tetano
Editor, Senior Moderator
J Intern Med
. 2021 Mar 30.
doi: 10.1111/joim.13292. Online ahead of print.
Cholestatic liver injury in COVID-19 is a rare and distinct entity and is associated with increased mortality
Ben L Da[SUP] 1 [/SUP], Kelly Suchman[SUP] 2 [/SUP], Nitzan Roth[SUP] 1 [/SUP], Anam Rizvi[SUP] 3 [/SUP], Maria Vincent[SUP] 4 [/SUP], Arvind J Trindade[SUP] 2 [/SUP], David Bernstein[SUP] 1 [/SUP], Sanjaya K Satapathy[SUP] 1 [/SUP], Northwell COVID-19 Research Consortium
Affiliations
Abstract
Current evidence indicates that the development of acute hepatocellular liver injury during coronavirus disease 2019 (COVID-19) is associated with more severe COVID-19 disease.[1] Since SARS-CoV2 is able to enter the liver via the ACE2 receptor proteins located on the epithelium of bile ducts, direct viral cholangiocyte injury is theoretically a possible pathogenic mechanism of the virus resulting in cholestatic liver injury.[2] Supporting this idea: a recent meta-analysis that reported serum alkaline phosphatase (ALP) elevations occurs in up to 13.7% of patients[3], a case series describing the clinical/histologic features of three patients with COVID-19 cholangiopathy[4], and a recent study reporting higher fatality rates in COVID-19 patients with cholestasis.[5].
Keywords: Alkaline Phosphatase; COVID-19; Cholestasis; Mortality; SARS-CoV2.
. 2021 Mar 30.
doi: 10.1111/joim.13292. Online ahead of print.
Cholestatic liver injury in COVID-19 is a rare and distinct entity and is associated with increased mortality
Ben L Da[SUP] 1 [/SUP], Kelly Suchman[SUP] 2 [/SUP], Nitzan Roth[SUP] 1 [/SUP], Anam Rizvi[SUP] 3 [/SUP], Maria Vincent[SUP] 4 [/SUP], Arvind J Trindade[SUP] 2 [/SUP], David Bernstein[SUP] 1 [/SUP], Sanjaya K Satapathy[SUP] 1 [/SUP], Northwell COVID-19 Research Consortium
Affiliations
- PMID: 33786906
- DOI: 10.1111/joim.13292
Abstract
Current evidence indicates that the development of acute hepatocellular liver injury during coronavirus disease 2019 (COVID-19) is associated with more severe COVID-19 disease.[1] Since SARS-CoV2 is able to enter the liver via the ACE2 receptor proteins located on the epithelium of bile ducts, direct viral cholangiocyte injury is theoretically a possible pathogenic mechanism of the virus resulting in cholestatic liver injury.[2] Supporting this idea: a recent meta-analysis that reported serum alkaline phosphatase (ALP) elevations occurs in up to 13.7% of patients[3], a case series describing the clinical/histologic features of three patients with COVID-19 cholangiopathy[4], and a recent study reporting higher fatality rates in COVID-19 patients with cholestasis.[5].
Keywords: Alkaline Phosphatase; COVID-19; Cholestasis; Mortality; SARS-CoV2.